Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

University of Toronto

$14,990.00

Market assessment for glucose-responsive microgels and microneedle patch technology

FY 2018-19

Summary
Our laboratory has invented a glucose-responsive device that can sense glucose levels and release native glucagon in real time in response to hypoglycemia. The device is a composite transdermal microneedle patch comprising a microneedle array and embedded microgel particles. The microparticles are made from three types of monomers - one provides glucose-responsive volume change, one for stabilizing native glucagon, and one for facilitating glucagon encapsulation. After the microneedle patch is applied, the microneedles penetrate the skin, swell quickly in the body fluid, and enable the microgels in contact with the fluid and glucose. The microgels sense the glucose concentrations and shrink at low glucose levels thus squeezing the encapsulated glucagon out. As a result, the glucagon diffuses out of the needles to the blood circulation and to the liver thereby increasing blood glucose levels. The entire process automatically proceeds without external intervention of patients or care givers. The invented microgel system can maintain the native structure and bioactivity of glucagon at body temperature and under the conditions of making microneedle array. In a T1D rat model, our laboratory has demonstrated that the transdermal patch is able to prevent hypoglycemia induced by excess insulin administration for up to 3 hours. This technology is the topic of US Provisional Patent 62/757,677 filed on 11/08/2018 - ""Device and Its Use for Preventing Hypoglycemia"". To commercialize these proprietary technologies into a product, Innovations and Partnerships Office (IPO) has contracted a consultant company to perform market analysis to address various market aspects. At the completion of the project, the company will provide a report which will guide us next move of commercialization activities including application for an NSERC I2I Phase 1 grant to optimize the composition and design of the device and develop larger scale methods. These activities will strengthen our position of attracting strategic development partners and investors in future.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
536712-2019
Name nom
Wu, XiaoYu
Department département
Pharmacy, Leslie Dan Faculty of
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2019
Award amount
14990
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Market assessment for glucose-responsive microgels and microneedle patch technology
Keyword
NSERC
Application summary
Our laboratory has invented a glucose-responsive device that can sense glucose levels and release native glucagon in real time in response to hypoglycemia. The device is a composite transdermal microneedle patch comprising a microneedle array and embedded microgel particles. The microparticles are made from three types of monomers - one provides glucose-responsive volume change, one for stabilizing native glucagon, and one for facilitating glucagon encapsulation. After the microneedle patch is applied, the microneedles penetrate the skin, swell quickly in the body fluid, and enable the microgels in contact with the fluid and glucose. The microgels sense the glucose concentrations and shrink at low glucose levels thus squeezing the encapsulated glucagon out. As a result, the glucagon diffuses out of the needles to the blood circulation and to the liver thereby increasing blood glucose levels. The entire process automatically proceeds without external intervention of patients or care givers. The invented microgel system can maintain the native structure and bioactivity of glucagon at body temperature and under the conditions of making microneedle array. In a T1D rat model, our laboratory has demonstrated that the transdermal patch is able to prevent hypoglycemia induced by excess insulin administration for up to 3 hours. This technology is the topic of US Provisional Patent 62/757,677 filed on 11/08/2018 - ""Device and Its Use for Preventing Hypoglycemia"". To commercialize these proprietary technologies into a product, Innovations and Partnerships Office (IPO) has contracted a consultant company to perform market analysis to address various market aspects. At the completion of the project, the company will provide a report which will guide us next move of commercialization activities including application for an NSERC I2I Phase 1 grant to optimize the composition and design of the device and develop larger scale methods. These activities will strengthen our position of attracting strategic development partners and investors in future.